Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a report of 12 patients.
- Author:
Yu-qian SUN
1
;
Lan-ping XU
;
Dai-hong LIU
;
Xiao-hui ZHANG
;
Wei HAN
;
Huan CHEN
;
Feng-rong WANG
;
Jing-zhi WANG
;
Yu WANG
;
Yu-hong CHEN
;
Kai-yan LIU
;
Xiao-jun HUANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; therapy; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation, Homologous; Young Adult
- From: Chinese Journal of Hematology 2013;34(2):113-116
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo retrospectively review the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelomonocytic leukemia (CMML).
METHODSThe engraftment, graft versus host disease (GVHD), infection, relapse and survival of 12 CMML patients received allo-HSCT were observed. The clinical outcome of allo-HSCT for CMML was analyzed.
RESULTSTwelve (7 males and 5 females) CMML patients with a median age of 39 years old received allo-HSCT including 7 from HLA-matched sibling and 5 from haploidentical related donors. All 12 patients achieved engraftment. The median time of neutrophil engraftment and platelet engraftment were 15 (11 - 20) days and 13 (11 - 18) days, respectively. 4 patients occurred acute GVHD, and 3 occurred chronic GVHD. After the median follow-up of 17.5 months (12 - 32 months), the overall survival, disease free survival and relapse rate were 66.7%, 66.7%, and 16.7%, respectively.
CONCLUSIONAllo-HSCT can improve the survival of patients with CMML, and is a effective therapy for CMML.
